What is Sihuan Pharmaceutical Holdings Group Net Margin %?
Sihuan Pharmaceutical Holdings GroupSHPHF 52 Net Margin % is 5.24% as of Dec. 2025, which is 49% below its 10-year median of 10.29. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 54.6% on this metric.
SHPHF'
s Net Margin % Range Over the Past 10 Years
Min: -95.66 Med: 10.29 Max: 55.53
Current: 6.85
SHPHF's Net Margin % is ranked better than 54.6% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SHPHF: 6.85
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sihuan Pharmaceutical Holdings Group Net Margin % Related Terms
Sihuan Pharmaceutical Holdings Group Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Net Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Net Margin % of 5.24% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 49% below median its historical median of 10.29. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #434 out of 956 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Sihuan Pharmaceutical Holdings Group's Net Margin % too high?
Sihuan Pharmaceutical Holdings Group's current Net Margin % of 5.24% is 49% below median its 10-year median of 10.29. The Drug Manufacturers industry median Net Margin % is 5.56. Sihuan Pharmaceutical Holdings Group's value of 5.24% is 5.8% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #434 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #434 out of 956 companies for Net Margin %. This puts Sihuan Pharmaceutical Holdings Group in the upper half of its industry. The industry median Net Margin % is 5.56. Sihuan Pharmaceutical Holdings Group's value of 5.24% is 5.8% below this benchmark. While the company's 10-year median is 10.29 vs. the industry median of 5.56, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Net Margin % of 5.24% is 5.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Net Margin % is 5.24%, which is 49% below median its own 10-year median of 10.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.13 — trading 13.5% below its estimated fair value. The current Net Margin % is 5.24%, which is 49% below median its 10-year median of 10.29 and 5.8% below the Drug Manufacturers industry median of 5.56. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Net Margin % is 5.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 13.5% below its estimated GF Value™ of $0.15.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
Net Margin %: 5.24% (49% below median its 10-year median of 10.29)
GF Value™: $0.15 vs. price of $0.13 (13.5% below fair value)
Industry Position: 5.8% below the Drug Manufacturers median (#434 of 956)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score
Get the complete analysis for SHPHF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
